The overall ratings of seven Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Genomic Health’s (NASDAQ:GHDX) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. In Portfolio Grader’s specific subcategory of Earnings Revisions, GHDX also gets an F. The stock price has dropped 11.5% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. As of June 19, 2013, 10.1% of outstanding Genomic Health shares were held short. The stock currently has a trailing PE Ratio of 164.90. For more information, get Portfolio Grader’s complete analysis of GHDX stock.
This week, Acorda Therapeutics (NASDAQ:ACOR) drops from a C to a D rating. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. To get an in-depth look at ACOR, get Portfolio Grader’s complete analysis of ACOR stock.
This is a rough week for Amarin (NASDAQ:AMRN). The company’s rating falls to D from the previous week’s C. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. In Earnings Growth, Earnings Revisions, Equity, and Cash Flow the stock gets F’s. Share prices fell 5.2% over the past month. As of June 19, 2013, 16.6% of outstanding Amarin shares were held short. For a full analysis of AMRN stock, visit Portfolio Grader.
Exelixis’ (NASDAQ:EXEL) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of June 19, 2013, 18.8% of outstanding Exelixis shares were held short. For more information, get Portfolio Grader’s complete analysis of EXEL stock.
Trius Therapeutics (NASDAQ:TSRX) earns a D this week, falling from last week’s grade of C. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. For a full analysis of TSRX stock, visit Portfolio Grader.
Discovery Laboratories (NASDAQ:DSCO) experiences a ratings drop this week, going from last week’s C to a D. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at DSCO, get Portfolio Grader’s complete analysis of DSCO stock.
Achillion (NASDAQ:ACHN) is having a tough week. The company’s rating falls from a C to a D. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also gets an F in Equity. As of June 19, 2013, 13.3% of outstanding Achillion shares were held short. For a full analysis of ACHN stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.